After seeing a rapid expansion in its business, Nemaura has moved to a newly built facility within Loughborough University Science and Enterprise Park. “It is a great location”, explained Dr Faz Chowdhury, CEO of Nemaura Pharma. “There are fantastic transport links, and we are within 15 miles of 5 excellent universities; there is an enormous pool of talent from which we can draw”. The new site includes several purpose built laboratories, including ones for pharmaceutical development and analytical chemistry. The aseptic production of injectables and topical dosages for clinical programmes will take place in a cleanroom suite, while a medical device prototyping laboratory will allow for 3D printing using medical grade materials.
The move was prompted by Nemaura’s sharp growth, particularly over the past two years. Over the previous twelve months, it has obtained CE approval for a class IIA diagnostic device and submitted an abbreviated new drug application to the US Food and Drug Administration for a transdermal therapeutic system for treating Alzheimer’s Disease. It has an array of products and technologies in preclinical and clinical development. These include diagnostics as well as drugs targeting conditions such as diabetes, hypertension, and migraine. “We needed much more space to accommodate our work”, noted Dr Chowdhury. Nemaura Pharma currently employs 24 people, and expects to increase the headcount to 35 people by the end of the year.
The company is involved in ongoing talks concerning additional licensing and collaborations. Over the next twelve months, Dr Chowdhury hopes that several of Nemaura’s products will obtain approval and enter the market. “We see enormous scope for our technologies”, he said. “Our cutting-edge new facilities will help foster an environment for creativity and innovation in the BioPharma field”. In which case, the move is likely to be temporary. “We expect to outgrow this facility within 2–3 years”, Dr Chowdhury concluded.
Cautionary Statement Regarding Forward Looking Statements
The statements in this release that are not historical facts may constitute forward-looking statements that are based on current expectations, and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura’s ongoing studies, the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies.
Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.